DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...

We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries "We are delighted with the addition of clinical sites in the EU and ...

Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. Despite technological and ...